… patient age and risk of relapse was also observed at this timepoint. Here we report the final
results of ISAV after … ) for dPCR analysis and the patient discontinued imatinib therapy. Q-RT-…

… Controlled clinical studies have shown that it is possible to discontinue imatinib, as shown …
ISAV study, age <45 years and a positive digital PCR status were shown to predict relapse. In …

… relapse after TKI discontinuation [59•]. The authors used ddPCR to analyze the RNA samples
of 175 patients from the STIM2 study who had discontinued imatinib … study showed that age…

… study enrolled patients intolerant of or resistant to imatinib. Of … or loss of MMR after
discontinuing imatinib were started on … is very similar across studies with most patients relapsing in …

… ENESTop study, patients resistant or intolerant to imatinib … recurrence was approximately
35% in patients with PCR values … patients enrolled on the Australian CML8 Study discontinued …

… The ISAV trial enrolled 107 CML patients treated with imatinib who discontinued the drug in
MR4.5 (Diral et al., 2019). At … dPCR was tested at study entry and in non-relapsed patients at …

… with imatinib about 40% of patients who discontinue treatment … of age on TFR has been
described: the ISAV study reported an … patients’ age and risk of relapse, with 95% of patients <45 …

… In the imatinib suspension and validation (ISAV) study, both age (<45 years) and a … PCR
status were shown to predict relapse in CML patients who discontinued treatment with imatinib (…

… from 2060 CML patients, who were treated using imatinib. … Younger patients are at higher
risk of relapse than older patients … confirmed by ISAV study with approximately the same age at …

… We report the results of the LAST study with a minimum follow… Molecular recurrence occurred
in 4% of patients with neither … TKI discontinuation, patients were hesitant to discontinue for …